Johnson & Johnson (NYSE:JNJ) Shares Sold by Integris Wealth Management LLC

Posted by Defense World Staff on Sep 24th, 2023

Integris Wealth Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 7,495 shares of the company’s stock after selling 100 shares during the period. Johnson & Johnson makes up 0.4% of Integris Wealth Management LLC’s investment portfolio, making the stock its 23rd largest position. Integris Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,241,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. Innova Wealth Partners raised its holdings in Johnson & Johnson by 8.7% in the 2nd quarter. Innova Wealth Partners now owns 1,912 shares of the company’s stock valued at $316,000 after acquiring an additional 153 shares during the last quarter. Falcon Wealth Planning raised its holdings in Johnson & Johnson by 41.0% in the 2nd quarter. Falcon Wealth Planning now owns 2,300 shares of the company’s stock valued at $381,000 after acquiring an additional 669 shares during the last quarter. Everhart Financial Group Inc. raised its holdings in Johnson & Johnson by 7.9% in the 2nd quarter. Everhart Financial Group Inc. now owns 9,207 shares of the company’s stock valued at $1,474,000 after acquiring an additional 675 shares during the last quarter. Consilium Wealth Advisory LLC increased its holdings in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Consilium Wealth Advisory LLC now owns 7,851 shares of the company’s stock worth $1,300,000 after buying an additional 111 shares during the last quarter. Finally, American Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 2.9% during the 2nd quarter. American Financial Advisors LLC now owns 3,139 shares of the company’s stock worth $520,000 after buying an additional 88 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $160.50 on Friday. The firm has a market cap of $417.13 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 3.27 and a beta of 0.54. The firm’s 50-day simple moving average is $166.51 and its 200-day simple moving average is $162.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.59 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Citigroup assumed coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 18th. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Finally, Raymond James decreased their price target on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating for the company in a research report on Tuesday, September 5th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $170.65.

View Our Latest Stock Report on JNJ

Insider Buying and Selling

In related news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.